STOCK TITAN

Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, will participate in the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 am PT. CEO Dr. Jonathan E. Lim will present an overview of the company and its RAS/MAPK pathway-focused pipeline in Elizabethan Room C of the Westin St. Francis Hotel, San Francisco. Additionally, Dr. Lim and CFO David M. Chacko will engage in one-on-one investor meetings. A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 41st annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder will present an overview of the company and its pipeline at 8:15 am Pacific Time on Monday, January 9, 2023, in Elizabethan Room C. Dr. Lim and David M. Chacko, M.D., chief financial officer, will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


FAQ

When is Erasca's presentation at the J.P. Morgan Healthcare Conference?

Erasca's presentation is scheduled for January 9, 2023, at 8:15 am Pacific Time.

Who will represent Erasca at the J.P. Morgan Healthcare Conference?

Dr. Jonathan E. Lim, CEO, and Dr. David M. Chacko, CFO, will represent Erasca.

Where is the J.P. Morgan Healthcare Conference being held?

The conference is being held at the Westin St. Francis Hotel in San Francisco, California.

How can I access the live webcast of Erasca's presentation?

The live audio webcast can be accessed through Erasca's official website during the event.

Will the presentation be available after the event?

Yes, an archived replay of the presentation will be available for 30 days following the event.

What is Erasca's focus in oncology?

Erasca is focused on discovering and developing therapies for RAS/MAPK pathway-driven cancers.

Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Stock Data

795.25M
282.50M
12.4%
77.06%
11.93%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO